Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy

SU Jili; ZHOU Xiaoshuang; FAN Xiuzhao; HAO Huiqiang; TIAN Shuangshuang; HUI Dongna; HAN Xiutao

doi:10.16766/j.cnki.issn.1674-4152.003060

Volume 21 Issue 7

Jul. 2023

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of General Practice > 2023 > 21(7): 1105-1108

SU Jili, ZHOU Xiaoshuang, FAN Xiuzhao, HAO Huiqiang, TIAN Shuangshuang, HUI Dongna, HAN Xiutao. Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy[J]. Chinese Journal of General Practice, 2023, 21(7): 1105-1108. doi: 10.16766/j.cnki.issn.1674-4152.003060

Citation:

SU Jili, ZHOU Xiaoshuang, FAN Xiuzhao, HAO Huiqiang, TIAN Shuangshuang, HUI Dongna, HAN Xiutao. Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy[J]. Chinese Journal of General Practice, 2023, 21(7): 1105-1108. doi: 10.16766/j.cnki.issn.1674-4152.003060

Citation:

SU Jili, ZHOU Xiaoshuang, FAN Xiuzhao, HAO Huiqiang, TIAN Shuangshuang, HUI Dongna, HAN Xiutao. Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy[J]. Chinese Journal of General Practice, 2023, 21(7): 1105-1108. doi: 10.16766/j.cnki.issn.1674-4152.003060

PDF( 482 KB)

Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy

doi: 10.16766/j.cnki.issn.1674-4152.003060

3.
The Fifth Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030000, China

Funds:

202103021222013

Received Date: 2022-09-26
Available Online: 2023-08-28

Abstract

Abstract

Objective To evaluate the effect of cyclophosphamide (CTX) combined with glucocorticoids (GS) in the treatment of primary IgA nephropathy (IgAN) with different degrees of hematuria, and provide reference for therapy of IgAN. Methods The clinical data of the primary IgAN patients treated with CTX and GS at the Shanxi Provincial People's Hospital from January 2015 to December 2021 were retrospectively collected. According to the degree of baseline hematuria, they were divided into mild hematuria group [urinary red blood cell count (URBC) < 30/high-power field (HPF)] and severe hematuria group (URBC≥30/HPF). The changes of renal function before therapy and 1st, 3rd and 6th month after therapy were compared between the two groups. The main outcomes were proteinuria remission rate, estimated glomerular filtration rate (eGFR) slope. The secondary outcomes were serum creatinine (Scr), blood urea nitrogen (BUN), eGFR and adverse reactions. Results A total of 132 IgAN patients were included, 95 cases in the mild hematuria group and 37 cases in the severe hematuria group. After therapy, proteinuria remission rate and eGFR slope in the severe hematuria group were higher than those in the mild hematuria group, and the difference between the two groups was statistically significant (all P < 0.05). Scr in the severe hematuria group showed a downward trend, while that in the mild hematuria group showed an upward trend, and the difference between the groups was statistically significant (P < 0.05). eGFR in both groups showed a trend of decreasing first and then increasing. The change of eGFR in the severe hematuria group was more obvious than that in the mild hematuria group (P < 0.05). BUN in both groups showed a trend of increasing first and then decreasing. The level of BUN in the severe hematuria group was lower than that in the mild hematuria group at all time points (P < 0.05). Conclusion The combination of CTX and GS has a good therapeutic effect on IgAN patients with severe hematuria. The level of hematuria before therapy may be latent basis for the selection of therapy decisions for IgAN.
- IgA nephropathy,
- Cyclophosphamide,
- Glucocorticoids,
- Haematuria,
- Clinical efficacy

FullText(HTML)

References(17)

References

[1]	MAIXNEROVA D, TESAR V. Emerging modes of treatment of IgA nephropathy[J]. Int J Mol Sci, 2020, 21(23): 9064. doi: 10.3390/ijms21239064
[2]	NATALE P, PALMER S C, RUOSPO M, et al. Immunosuppressive agents for treating IgA nephropathy[J]. Cochrane Database Syst Rev, 2020, 3(3): CD003965. DOI: 10.1002/14651858.CD003965.
[3]	范晶, 黄冠文, 包继文, 等. IgA肾病预后相关危险因素分析[J]. 中华全科医学, 2022, 20(5): 731-734, 735. doi: 10.16766/j.cnki.issn.1674-4152.002441 FAN J, HUANG G W, BAO J W, et al. Analysis of risk factors for the prognosis of IgA nephropathy[J]. Chinese Journal of General Practice, 2022, 20(5): 731-734, 735. doi: 10.16766/j.cnki.issn.1674-4152.002441
[4]	Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S): S1-S276.
[5]	YU G Z, GUO L, DONG J F, et al. Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study[J]. Am J Kidney Dis, 2020, 76(1): 90-99. doi: 10.1053/j.ajkd.2019.11.008
[6]	LEVEY A S, GANSEVOORT R T, CORESH J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US food and drug administration and european medicines agency[J]. Am J Kidney Dis, 2020, 75(1): 84-104. doi: 10.1053/j.ajkd.2019.06.009
[7]	WONG M G, LV J C, HLADUNEWICH M A, et al. The therapeutic evaluation of steroids in IgA nephropathy global (TESTING) study: trial design and baseline characteristics[J]. Am J Nephrol, 2021, 52(10-11): 827-836. doi: 10.1159/000519812
[8]	CHEN T Y, LI X, LI Y X, et al. Prediction and risk stratification of kidney outcomes in IgA nephropathy[J]. Am J Kidney Dis, 2019, 74(3): 300-309. doi: 10.1053/j.ajkd.2019.02.016
[9]	EBBESTAD R, SANAEI N M, LUNDBERG S. Long-term outcomes of patients with IgA nephropathy categorized by the international IgAN risk prediction tool and by the degree of hematuria at diagnosis[J]. Nephron, 2022, 146(6): 573-583. doi: 10.1159/000525001
[10]	谷晓娟, 王惠芳, 尹文娟, 等. 伴有肉眼血尿的IgA肾病患者临床病理特点及预后分析[J]. 中华全科医师杂志, 2021, 20(5): 581-586. doi: 10.3760/cma.j.cn114798-20200830-00948 GU X J, WANG H F, YIN W J, et al. Clinicopathological characteristics and prognosis of IgA nephropathy patients with gross hematuria[J]. Chinese Journal of General Practitioners, 2021, 20(5): 581-586. doi: 10.3760/cma.j.cn114798-20200830-00948
[11]	LUO R, GUO S M, LI Y Q, et al. Plasma fractalkine levels are associated with renal inflammation and outcomes in immunoglobulin A nephropathy[J]. Nephrol Dial Transplant, 2019, 34(9): 1549-1558. doi: 10.1093/ndt/gfy169
[12]	CORMICAN S, GRIFFIN M D. Fractalkine (CX3CL1) and its receptor CX3CR1: a promising therapeutic target in chronic kidney disease?[J]. Front Immunol, 2021, 12: 664202. DOI: 10.3389/fimmu.2021.664202.
[13]	PATTRAPORNPISUT P, AVILA-CASADO C, REICH H N. IgA Nephropathy: core curriculum 2021[J]. Am J Kidney Dis, 2021, 78(3): 429-441. doi: 10.1053/j.ajkd.2021.01.024
[14]	陈晓洁, 许日聪, 胡豪飞, 等. 血红蛋白水平与IgA肾病患者肾脏预后的关系[J]. 中华肾脏病杂志, 2021, 37(9): 730-738. doi: 10.3760/cma.j.cn441217-20210120-00108 CHEN X J, XU R C, HU H F, et al. Association between hemoglobin levels and renal progression in patients with IgA nephropathy[J]. Chinese Journal of Nephrology, 2021, 37(9): 730-738. doi: 10.3760/cma.j.cn441217-20210120-00108
[15]	ZHU B, LIU W H, YU D R, et al. The association of low hemoglobin levels with IgA nephropathy progression: a two-center cohort study of 1, 828 cases[J]. Am J Nephrol, 2020, 51(8): 624-634. doi: 10.1159/000508770
[16]	ILIOPOULOU V N, CHARKOFTAKI G, COOPER J C, et al. Population pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide metabolite in patients with autoimmune glomerulonephritis[J]. J Pharm Pharmacol, 2021, 73(12): 1683-1692. doi: 10.1093/jpp/rgab135
[17]	MA F, YANG X X, ZHOU M L, et al. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide[J]. J Nephrol, 2020, 33(6): 1241-1250. doi: 10.1007/s40620-020-00752-x

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (283) PDF downloads(7)

Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy

doi: 10.16766/j.cnki.issn.1674-4152.003060

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Efficacy of cyclophosphamide combined with glucocorticoids therapy with different degrees of hematuria IgA nephropathy

doi: 10.16766/j.cnki.issn.1674-4152.003060

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content